1. Effects of azacitidine in 93 patients with IDH1/2 mutated acute myeloid leukemia/myelodysplastic syndromes: a French retrospective multicenter study. Issue 2 (28th January 2021) Authors: Willekens, C.; Rahme, R.; Duchmann, M.; Vidal, V.; Saada, V.; Broutin, S.; Delahousse, J.; Renneville, A.; Marceau, A.; Clappier, E.; Uzunov, M.; Rossignol, J.; Pascal, L.; Simon, L.; Micol, J. B.; Pasquier, F.; Raffoux, E.; Preudhomme, C.; Quivoron, C.; Itzykson, R. Journal: Leukemia & lymphoma Issue: Volume 62:Issue 2(2021) Page Start: 438 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Effects of azacitidine in 93 patients with IDH1/2 mutated acute myeloid leukemia/myelodysplastic syndromes: a French retrospective multicenter study. Issue 2 (28th January 2021) Authors: Willekens, C.; Rahme, R.; Duchmann, M.; Vidal, V.; Saada, V.; Broutin, S.; Delahousse, J.; Renneville, A.; Marceau, A.; Clappier, E.; Uzunov, M.; Rossignol, J.; Pascal, L.; Simon, L.; Micol, J. B.; Pasquier, F.; Raffoux, E.; Preudhomme, C.; Quivoron, C.; Itzykson, R. Journal: Leukemia & lymphoma Issue: Volume 62:Issue 2(2021) Page Start: 438 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. SERUM 2‐HYDROXYGLUTARATE, A PREDICTIVE BIOMARKER OF THE PRESENCE OF IDH2 MUTATIONS IN AITL PATIENTS. (June 2017) Authors: Broutin, S.; Dupuy, A.; Koscielny, S.; Fataccioli, V.; Lemonnier, F.; de Leval, L.; Robe, C.; Pujals, A.; Safar, V.; Delarue, R.; Delfau‐Larue, M.H.; Ribrag, V.; Haioun, C.; Gaulard, P.; Paci, A. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 392 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗